Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01006876 · ClinicalTrials.gov registry record · Phase 3
Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation
A Phase 3 study, sponsored by Texas Cardiac Arrhythmia Research Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,584
- Enrollment target
NCT01006876: Completed Phase 3 study, sponsored by Texas Cardiac Arrhythmia Research Foundation.
NCT01006876 is a Phase 3 study that has completed, run by Texas Cardiac Arrhythmia Research Foundation. The registered enrollment target is 1,584 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (105% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01006876, a Phase 3 study, has completed, sponsored by Texas Cardiac Arrhythmia Research Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,584 participants
- Enrollment target
Study Summary
This study aims to explore the risk of periprocedural thromboembolic events in continuous versus interrupted Coumadin therapy in a large, randomized high-risk patient population undergoing radio-frequency catheter ablation for atrial fibrillation.
Interventions
- DRUG Coumadin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,584 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
What the finished NCT01006876 record still lists
NCT01006876 is an interventional study that assigns participants to a tested intervention. Its 1,584 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (105% higher).
The record links to 0 conditions, and to 1 intervention - of which Coumadin is the first listed.
NCT01006876 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01006876 about?
NCT01006876 is a clinical study titled "Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation". This study aims to explore the risk of periprocedural thromboembolic events in continuous versus interrupted Coumadin therapy in a large, randomized high-risk patient population undergoing radio-frequency catheter ablation for atrial fibrillation.
What is the current status of trial NCT01006876?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,584 participants. The study started on 2010-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01006876?
The interventions under investigation include: Coumadin (DRUG).
Who is sponsoring clinical trial NCT01006876?
This trial is sponsored by Texas Cardiac Arrhythmia Research Foundation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01006876's enrollment target sits among peer trials
1,584 149th of 2000 higher than 1,852 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05483855 · 1,580 participants
Telehealth-delivered HealthcaRe to ImproVe Care
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT05243797 · 1,594 participants · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia